Developmental Research Program (DRP)

发展研究计划 发展研究计划（DRP）是杜克癌症健康差异的重要组成部分 （DCHD）P20孢子，支持（1）与癌症相关的转化潜力的试点研究项目 差异和（2）来自其他领域的早期和经验丰富的调查人员的参与， 转化性癌症研究鼓励项目测试新颖的概念和范式， 进入该领域的方法，以进一步推进我们对癌症健康差异的理解，并改善 预防、诊断、拦截和/或治疗。DRP将专门针对具有强大 有可能发展成为我们计划的DCHD P50 SPORE应用程序或独立研究的完整项目 项目（如NIH R 01或类似的供资机制）。将特别注意促进参与 妇女和少数民族。共同主任杰拉德布洛，医学博士，博士和凯瑟琳波拉克的协调努力， 博士，与DRP科学审查委员会（DRP-SRC），将确保一个积极主动，富有成效的DRP， 优先考虑有影响力的试点项目和教师招聘，并很好地融入整个P20 SPORE。的 DRP将识别和支持有价值的基础，转化，人口或临床研究项目， 在预防、诊断、拦截或治疗水平上影响癌症差异的可能性很高 (Aim 1）;吸引优秀的新的和/或有经验的研究人员，目前不从事癌症差异， 进行癌症差异研究（目标2）;促进合作转化研究，以测试新概念 以及与癌症预防、诊断、拦截或治疗方面的差异相关的范例（目标3）;以及 评估资助项目的进展情况，并促进其发展成为完整的SPORE项目或独立的SPORE项目。 资助项目（目标4）。为了实现这些目标，DRP每年将奖励10万美元，资助至少一个 每年都有项目。获奖者如满意，将有资格获得延长一年的资助 取得了进展，并提出了可接受的建议和第二年的计划。招徕策略 DRP申请将包括直接征求所有教师在杜克癌症研究所，杜克学校 医学和杜克大学。此外，全国其他机构的癌症差异研究项目 将联系，并将在适当的临床和科学期刊上刊登广告，以吸引 来自杜克以外的协作应用程序。所有DRP应用程序都将经过透明的多层对等 审查过程。DRP获奖者将被要求轮流提交其项目的进度报告 在每两周一次的执行委员会会议上，他们将收到反馈。DRP及其流程 作为DCHD P20 SPORE评估的一部分，将每年进行一次评估，并在下一次评估中进行改进。 招标、审查和授予的周期。

ABSTRACT – Developmental Research Program The Developmental Research Program (DRP) is a critical component of the Duke Cancer Health Disparities (DCHD) P20 SPORE, supporting (1) pilot research projects with translational potential relevant to cancer disparities and (2) the participation of early stage and experienced investigators from other fields to work in translational cancer research. Projects are encouraged to test novel concepts and paradigms that bring new approaches into the field to further advance our understanding of cancer health disparities and to improve prevention, diagnosis, interception, and/or treatment. The DRP will specifically target projects that have a strong likelihood of developing into full projects for our planned DCHD P50 SPORE application or independent research projects (e.g. NIH R01 or similar funding mechanisms). Special attention will be given to promoting participation of women and minorities. The coordinated efforts of Co-Directors Gerard Blobe, MD, PhD, and Kathryn Pollak, PhD, with the DRP Scientific Review Committee (DRP-SRC), will ensure a proactive, productive DRP that prioritizes impactful pilot projects and faculty recruitment, and is well integrated into the overall P20 SPORE. The DRP will identify and support meritorious basic, translational, population, or clinical research projects that have a high probability of impacting cancer disparities at the level of prevention, diagnosis, interception, or treatment (Aim 1); attract outstanding new and/or experienced investigators, currently not working on cancer disparities, to pursue cancer disparities research (Aim 2); facilitate collaborative translational research to test novel concepts and paradigms relevant to cancer disparities in prevention, diagnosis, interception, or treatment (Aim 3); and evaluate progress on funded projects and facilitate their evolution into full SPORE projects or into independently funded projects (Aim 4). To accomplish these Aims, the DRP will award $100,000 each year to fund at least one promising project per year. Awardees will be eligible for renewed funding for one additional year, if satisfactory progress is made and an acceptable proposal and plan for the second year are presented. Strategies to solicit DRP applications will include direct solicitation to all faculty in the Duke Cancer Institute, Duke School of Medicine, and Duke University. In addition, cancer disparities research programs at other institutions nationwide will be contacted, and advertisements will be placed in appropriate clinical and scientific journals to attract collaborative applications from outside of Duke. All DRP applications will undergo a transparent multi-tiered peer review process. DRP awardees will be required to present progress reports on their projects on a rotating basis at the bi-weekly Executive Committee meetings, where they will receive feedback. The DRP and its processes will be evaluated annually as part of the DCHD P20 SPORE evaluation, and improvements instituted for the next cycle of solicitation, review, and award.